Medical News / From ESC congress 2023 - FRAIL-AF: Switching to NOACs in Older, Frail Patients Linked to Increased Bleeding Risk

For frail elderly patients with atrial fibrillation, switching from a vitamin K antagonist (VKA) treatment to a non-vitamin K antagonist oral anticoagulant (NOAC) could increase risk of bleeding complications. Results of the FRAIL-AF study, which was billed as the first randomized NOAC trial exclusively including frail older patients, suggest the rate of bleeding events was 69% greater among those who switched to a NOAC without significant benefit for thromboembolic events. Source: MDMag. To view the third party content, kindly click on the link below or read more. You will then leave this site and enter a third party site.

read more

Data from an analysis of the landmark CLEAR Outcomes trial suggests bempedoic acid could prove useful ... read more
At the European Society of Cardiology (ESC) Congress 2023, the spotlight was on mavacamten and its ... read more
Data from VALOR-HCM LTE suggest use of the cardiac myosin inhibitor mavacamten (Camzyos) could reduce the ... read more
For endocrinologists and the diabetes care team, GLP-1 receptor agonists have been a familiar face for ... read more